<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030116</url>
  </required_header>
  <id_info>
    <org_study_id>SQXS20181221</org_study_id>
    <nct_id>NCT05030116</nct_id>
  </id_info>
  <brief_title>Clinical Trial for 'Shen Qu Xiao Shi' Oral Liquid in the Treatments of Children's Functional Dyspepsia</brief_title>
  <official_title>Comparison of Shenqu Xiaoshi Oral Liquid and Domperidone Suspension in the Treatment of Functional Dyspepsia in Children: a Randomized, Double-blind, Double-simulated, Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With domperidone suspension as the control, the effect of shenqu xiaoshi oral liquid on&#xD;
      functional dyspepsia in children was evaluated objectively through multi-center, randomized,&#xD;
      double-blind and double-simulation experiment, which alleviated the clinical symptoms,&#xD;
      restored and promoted the normal growth and development of children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Actual">May 23, 2020</completion_date>
  <primary_completion_date type="Actual">May 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total effective rate</measure>
    <time_frame>Treatment for two weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical symptom scores</measure>
    <time_frame>Treatment for one/two week(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total effective rate</measure>
    <time_frame>Two weeks after stopping the medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food intake</measure>
    <time_frame>Treatment for one/two week(s) and two weeks after stopping the medication</time_frame>
    <description>Food intake was measured by a scale filling by subjects or their parents. Scores range from 0 to 3. Higher score represents greater reduction in food intake and 0 means unchanged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>Treatment for one/two week(s) and two weeks after stopping the medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The meal time</measure>
    <time_frame>Treatment for one/two week(s) and two weeks after stopping the medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin</measure>
    <time_frame>Treatment for two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shenqu Xiaoshi oral liquid</intervention_name>
    <description>Shenqu Xiaoshi oral liquid</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone suspension</intervention_name>
    <description>Domperidone suspension</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children aged 3-14 years, regardless of gender;&#xD;
&#xD;
          2. Meet 1 or more conditions: (1) full after dinner; (2) early full; (3) abdominal pain,&#xD;
             and defecation has nothing to do; After appropriate evaluation, symptoms cannot be&#xD;
             fully explained by other diseases; Or have other symptoms of dyspepsia, but not caused&#xD;
             by other diseases;&#xD;
&#xD;
          3. Have symptoms at least 2 months before diagnosis and at least 4 days per month;&#xD;
&#xD;
          4. During the 2-week leading-in period, no drugs were used to treat infantile anorexia&#xD;
             and functional dyspepsia, and good eating habits were established. The patients were&#xD;
             fed on time and still had the above-mentioned symptoms of anorexia and functional&#xD;
             dyspepsia; The symptom score was 3.&#xD;
&#xD;
          5. The legal guardian of the child should sign the informed consent form. If the child is&#xD;
             10 years old or older, they should sign the informed consent form and agree to&#xD;
             participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anorexia and dyspepsia caused by anorexia or dyspepsia caused by the influence of&#xD;
             certain drugs or other confirmed diseases, such as erosive gastritis and gastric&#xD;
             ulcer;&#xD;
&#xD;
          2. Children with severe malnutrition;&#xD;
&#xD;
          3. Children with abnormal ecg, liver and kidney functions, nervous system, respiratory&#xD;
             system and endocrine system considered by the investigator;&#xD;
&#xD;
          4. Children with mental disorders, dementia and unclear speech;&#xD;
&#xD;
          5. Lactose intolerance or allergy to drug ingredients, or allergy to traditional Chinese&#xD;
             medicine;&#xD;
&#xD;
          6. Children who have participated in other clinical trials or are participating in&#xD;
             clinical trials of other drugs within 12 weeks; According to the judgment of the&#xD;
             researchers, there are other diseases or conditions that reduce the possibility of&#xD;
             enrollment or complicate enrollment, such as unstable living environment and&#xD;
             inconvenient transportation, which are easy to cause loss and follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional dyspepsia</keyword>
  <keyword>children</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

